HMGCR and RASopathy: Given the increased potency of simvastatin to reduce HMG-CoA reductase, it would suggest that the previously demonstrated rescue of RASopathy phenotypes by statins is not mediated by attenuation of RAS farnesylation but rather through an unknown mechanism that is absent or less potent for simvastatin.